Diabetes drugs act as powerful curb for immune cells in controlling inflammation

diabetes
Credit: CC0 Public Domain

When tissue is damaged, one of the body's first inflammatory immune-system responders are macrophages, cells which are commonly thought of as "construction workers" that clear away damaged tissue debris and initiate repair. However, prolonged inflammation promotes the progression of many diseases, including obesity. Now, a common class of drugs used to treat diabetes has been found to exert a powerful check on macrophages by controlling the metabolic fuel they use to generate energy. Keeping macrophages from going overboard on the job may inhibit the onset of obesity and diabetes following tissue inflammation. These findings are detailed in a study published online this month in Genes and Development led by Mitchell Lazar, MD, Ph.D., director of the Institute for Diabetes, Obesity, and Metabolism in the Perelman School of Medicine at the University of Pennsylvania.

Overnutrition, an excess intake of calories which can lead to obesity, causes a buildup of fat that can significantly damage tissues. When this happens, macrophages infiltrate the affected tissues, sequester free fatty acids, and help repair damaged tissue—essentially acting as a protector of the body during times of metabolic stress. However, extended stress on these tissues activates inflammatory characteristics in macrophages that contribute to several systemic effects of obesity including diabetes, atherosclerosis, and cardiovascular disease.

Diabetes drugs called thiazolidinediones (TZDs) control gene expression by targeting a factor called PPAR gamma. "It was known that PPAR gamma is important for macrophages to enter an active state to reduce inflammation and promote wound healing," said co-first author Victoria Nelson, Ph.D., postdoctoral fellow in Lazar's lab. "But we wanted to know if this was controlled through macrophage metabolism."

Lazar's team found that the TZDs, working through PPAR gamma, promote the metabolism of an amino acid called glutamine, a protein building block necessary for macrophage activation. The team found that lacking PPAR gamma are unable to use glutamine as an energy source and therefore are more susceptible to inflammatory stimulation.

"These findings are highly relevant to treatment strategies that use TZDs for diabetes and enhance the justification for using TZDs to treat that accompanies many types of disease, including and ," Lazar said.


Explore further

Fat production and burning are synchronized in livers of mice with obesity

More information: Victoria L. Nelson et al, PPARγ is a nexus controlling alternative activation of macrophages via glutamine metabolism, Genes & Development (2018). DOI: 10.1101/gad.312355.118
Journal information: Genes & Development

Citation: Diabetes drugs act as powerful curb for immune cells in controlling inflammation (2018, July 27) retrieved 19 September 2019 from https://medicalxpress.com/news/2018-07-diabetes-drugs-powerful-curb-immune.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Jul 29, 2018
the word 'inflammation' alone, is practically useless to us in general, because in reality, the Mechanisms are so varied, and sometimes opposite, across different conditions and individuals, that what may seem to somehow apply ends up being so convoluted and contradicted that we are left mislead or non-informed. What applies for 'one' type of inflammation often does not apply at all for another. It is the farthest thing from a 'one word fits all' word. It seems the word must always be qualified as carefully as possible to describe exactly what path and type, with every usage of the word. One word is just not enough. In other words, if we can't say something specific about it, we almost might as well not say it. Likewise with the word 'immune system'.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more